Safety and Feasibility of ADRCs (Adipose Derived Regenerative Cells) in Patients With Grade II Hamstring Tears

Withdrawn before enrolling · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Muscle Tear

In brief

To evaluate the safety and feasibility of adipose-derived regenerative cells injected into tears of the hamstring muscle.

Key facts

Study ID

NCT02045888

Run by

Cytori Therapeutics

People needed

0

Starts

2014-01-01

Expected to finish

2014-11-01

Last updated by the study team

2014-11-21

Who can join

Age: 20 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Grade II tears (≥5%) of the hamstring
• Weakness or inability to use affected muscle
• Ability to safely undergo liposuction

You may not qualify if…

• Tears restricted to the ligament (i.e. no muscle tear)
• Known spine or disc disease or sciatic nerve disease
• Known neuromuscular disease
• Pregnant or lactating status
• Any condition requiring immunosuppressive medication or use of systemic steroids
• Known history of HIV, or has active Hepatitis B or active Hepatitis C
• Cancer requiring chemotherapy or resection within the last 5 years (other than basal cell carcinoma)

Where it is running

• Study site — Los Angeles, California, United States
• Study site — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.